{
    "clinical_study": {
        "@rank": "146175", 
        "arm_group": {
            "arm_group_label": "LDK378", 
            "arm_group_type": "Experimental", 
            "description": "Single-agent LDK378"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to estimate the maximum tolerated dose of LDK378 as a single\n      agent, assess safety, tolerability and anti-tumor activity and characterize single and\n      multiple-dose pharmacokinetics when administered orally to pediatric patients with\n      ALK-activated tumors."
        }, 
        "brief_title": "Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Anaplastic Lymphoma Kinase (ALK)", 
        "condition_browse": {
            "mesh_term": "Lymphoma"
        }, 
        "detailed_description": {
            "textblock": "LDK378 is a novel inhibitor of ALK that is active in a broad range of ALK-activated tumor\n      models, including models driven by mutated versions of ALK known to be resistant to\n      crizotinib, and by ALK gene amplification.\n\n      The primary purpose of this study is to determine the maximum tolerated dose and/or\n      recommended dose for expansion in pediatric patients, and to delineate a clinical dose to be\n      used in any future pediatric studies. This study will also assess the safety, tolerability,\n      PK and preliminary evidence of antitumor activity of LDK378 in pediatric patients with\n      neuroblastoma, and other ALK-activated tumors."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with a locally advanced or metastatic malignancy that has progressed\n             despite standard therapy, or for which no effective standard therapy exists\n\n          -  Age  \u2265 12 months and \u2264 17 years\n\n          -  The tumor must carry a genetic alteration of ALK\n\n          -  Patients must have evaluable or measurable disease\n\n        Exclusion criteria:\n\n          -  Symptomatic central nervous system (CNS) metastases who are neurologically unstable\n             or require increasing doses of steroids or local CNS-directed therapy (such as\n             radiotherapy, surgery or intrathecal chemotherapy) to control their CNS disease\n\n          -  Clinically significant, uncontrolled heart disease\n\n          -  Inadequate end organ function as defined by specified laboratory values\n\n          -  Use of medications that are known to be strong inhibitors or inducers of CYP3A4/5\n             that cannot be discontinued at least 1 week prior to start of treatment with LDK378\n             and for the duration of the study\n\n          -  Use of medications that are mainly metabolized by CYP3A4/5 or CYP2C9 that cannot be\n             discontinued at least 1 week prior to start of treatment with LDK378 and for the\n             duration of the study.\n\n          -  History of interstitial lung disease or interstitial pneumonitis, including\n             clinically significant radiation pneumonitis\n\n          -  Medications with a known risk of prolongation of QT interval"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742286", 
            "org_study_id": "CLDK378X2103", 
            "secondary_id": "2012-002074-31"
        }, 
        "intervention": {
            "arm_group_label": "LDK378", 
            "description": "LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via NG/G tube", 
            "intervention_name": "LDK378", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "pediatric, anaplastic lymphoma kinase, ALK-activated tumors, neuroblastoma, rhabdomyosarcoma, anaplastic large-cell lymphoma, inflammatory myofibroblastic tumor", 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles UCLA LeConte Location"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "katherine.garrett@choa.org", 
                    "last_name": "Katherine Garrett", 
                    "phone": "404-785-3535"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30342"
                    }, 
                    "name": "Children's Healthcare of Atlanta Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Howard Katzenstein", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Mei_yang@dfci.harvard.edu", 
                    "last_name": "Mei Yang", 
                    "phone": "617-582-7169"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Suzanne Shusterman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cabezonv@mskcc.org", 
                    "last_name": "Virginia Cabezon", 
                    "phone": "646-888-5716"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center SC - 7"
                }, 
                "investigator": {
                    "last_name": "Shakeel Modak", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "renee.doughman@cchmc.org", 
                    "last_name": "Renee Doughman", 
                    "phone": "513-636-9419"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229-3039"
                    }, 
                    "name": "Cincinnati Children's Hospital Medical Center Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Brian Weiss", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "letitia.williams@stjude.org", 
                    "last_name": "Letitia Anne Williams", 
                    "phone": "+1 901 595 2388"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105-2794"
                    }, 
                    "name": "St. Jude's Children's Research Hospital Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Alberto Pappo", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mxtucker@txch.org", 
                    "last_name": "Meg Tucker-Hall", 
                    "phone": "832-824-4570"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Texas Children's Hospital Dept of Oncology"
                }, 
                "investigator": {
                    "last_name": "Eric Schafer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Randwick", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2130"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3052"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1X8"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75231"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45147"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50924"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20133"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "110 744"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "135-710"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3015 GJ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28009"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B4 6NH"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada", 
                "France", 
                "Germany", 
                "Italy", 
                "Korea, Republic of", 
                "Netherlands", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "cycle = within the first 21 days of patient's first dose", 
            "measure": "Incidence rate of Dose Limiting Toxicities (DLT)", 
            "safety_issue": "Yes", 
            "time_frame": "up to day 21 after the patient's first dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742286"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Characterize the safety and tolerability of LDK378 in the pediatric patients", 
                "measure": "Number of patients with Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LDK378 in the pediatric patients", 
                "measure": "Changes in laboratory values", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LDK378 in the pediatric patients", 
                "measure": "Assessments of physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LDK378 in the pediatric patients", 
                "measure": "Assessments of vital signs and electrocardiograms", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LDK378 in the pediatric patients", 
                "measure": "Plasma concentration time profiles", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LDK378", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LDK378", 
                "measure": "Duration of response (DoR)", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LDK378 as per RECIST 1.1", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assess the anti-tumor activity of LDK378 as per International Working Group (IWG) criteria", 
                "measure": "Changes in disease burden in patients with lymphoma", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize the safety and tolerability of LDK378 in the pediatric patients", 
                "measure": "Number of patients with serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple-dose PK of LDK378 in pediatric patients", 
                "measure": "Pharmacokinetics (PK) parameter: AUClast", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple-dose PK of LDK378 in pediatric patients", 
                "measure": "PK parameter: AUCtau", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple-dose PK of LDK378 in pediatric patients", 
                "measure": "PK parameter: Cmin", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple-dose PK of LDK378 in pediatric patients", 
                "measure": "PK parameter: Cmax", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple-dose PK of LDK378 in pediatric patients", 
                "measure": "PK parameter: Tmax", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple-dose PK of LDK378 in pediatric patients", 
                "measure": "PK parameter: Racc", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple-dose PK of LDK378 in pediatric patients", 
                "measure": "PK parameter: t1/2", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Characterize single and multiple-dose PK of LDK378 in pediatric patients", 
                "measure": "PK parameter: acc", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}